肝细胞腺瘤在MRI随访中的长期演变
回顾性纳入2004年1月至2015年12月病理证实的118例肝细胞腺瘤患者,分析MRI长期演变。中位随访5年,78%病灶稳定或消退;多发腺瘤更易进展,其中肝细胞核因子1α失活型进展率高于炎症型(42% vs 19%,P=.04)。
要点
- 中位随访5年,78%肝细胞腺瘤在MRI上稳定或消退。
- 多发腺瘤比单发更易进展,肝细胞核因子1α失活型进展率最高。
- 单发腺瘤切除后新发病灶仅见于有进展风险的腺瘤。
核心结论
- 长期MRI随访显示78%的肝细胞腺瘤稳定或消退。
- 单发肝细胞腺瘤切除后,新发病灶仅见于有进展风险的腺瘤。
- 多发肝细胞腺瘤更易出现进展,肝细胞核因子1α失活型是最常见的进展亚型。
研究设计与样本
- 回顾性研究,纳入2004年1月至2015年12月病理证实的118例单发或多发肝细胞腺瘤患者。
- 患者平均年龄40岁±10(标准差),其中女性108例;单发腺瘤41例(平均年龄40岁±14,女性36例),多发腺瘤77例(平均年龄40岁±10,女性72例)。
- β-catenin突变型腺瘤和含恶性灶的腺瘤被视为有进展风险。
- 采用实体瘤疗效评价标准第1.1版评估肿瘤演变,统计方法包括Student t检验、Mann-Whitney检验、χ2检验、Fisher精确检验和McNemar检验。
关键影像表现/征象
- 中位随访5年,单发腺瘤41例中37例(90%)稳定或消退,多发腺瘤77例中55例(71%)稳定或消退。
- 单发腺瘤切除后29例中仅2例(7%)出现新发病灶,两例均有进展风险的腺瘤。
- 多发腺瘤中,肝细胞核因子1α失活型进展率高于炎症型(26例中11例[42%] vs 37例中7例[19%],P=.04)。
诊断标准与关键数值
- 采用实体瘤疗效评价标准第1.1版评估肿瘤演变。
- β-catenin突变型腺瘤和含恶性灶的腺瘤被视为有进展风险。
- 多发腺瘤中,肝细胞核因子1α失活型进展率42%(11/26)vs 炎症型19%(7/37),P=.04。
- 肝细胞核因子1α失活型口服避孕药使用比例28/32(88%)vs 炎症型45/45(100%),P=.03;使用时长平均12.0年±7.5 vs 19.2年±9.2,P=.001。
临床应用与阅片要点
- MRI长期随访可用于监测肝细胞腺瘤的稳定、消退或进展。
- 单发腺瘤切除后新发病灶仅见于有进展风险的腺瘤。
- 多发腺瘤患者更易出现进展,肝细胞核因子1α失活型是最常见的进展亚型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Hepatocellular adenomas (HCAs) are rare benign liver tumors. Guidelines recommend continued surveillance of patients diagnosed with HCAs, but these guidelines are mainly based on small studies or expert opinion. Purpose To analyze the long-term evolution of HCAs, including solitary and multiple lesions, and to identify predictive features of progression with MRI. Materials and Methods In a retrospective study, patients diagnosed with pathologically proven solitary or multiple HCAs between January 2004 and December 2015 were included; β-catenin-mutated HCAs and HCAs with foci of malignancy were considered to be at risk for progression. MRI examinations were analyzed, and tumor evolution was evaluated by using Response Evaluation Criteria in Solid Tumors, version 1.1. Student t, Mann-Whitney, χ2, Fisher exact, and McNemar tests were used, as appropriate. Results In total, 118 patients (mean age, 40 years ± 10 [standard deviation]; 108 women) were evaluated, including 41 with a solitary HCA (mean age, 40 years ± 14; 36 women) and 77 with multiple HCAs (mean age, 40 years ± 10; 72 women). At a median follow-up of 5 years, 37 of 41 (90%) patients with a solitary HCA and 55 of 77 (71%) patients with multiple HCAs showed stable or regressive disease. After resection of solitary HCAs, new lesions appeared in only two of 29 (7%) patients, both of whom had HCAs at risk of progression. In patients with multiple HCAs, hepatocyte nuclear factor 1α-inactivated HCAs showed a higher rate of progression compared with inflammatory HCAs (11 of 26 [42%] vs seven of 37 [19%], P = .04) despite lower use (28 of 32 patients [88%] vs 45 of 45 patients [100%]; P = .03) and shorter duration (mean, 12.0 years ± 7.5 vs 19.2 years ± 9.2; P = .001) of oral contraceptive intake. Conclusion Long-term MRI follow-up showed that 78% of hepatocellular adenomas had long-term stability or regression. After resection of solitary hepatocellular adenomas, new lesions occurred only in hepatocellular adenomas at risk of progression. Patients with multiple hepatocellular adenomas were more likely to show progressive disease, with hepatic nuclear factor 1α-inactivated hepatocellular adenomas being the most common subtype showing progression. © RSNA, 2020 Online supplemental material is available for this article.
引用
- Vernuccio F, Ronot M, Dioguardi Burgio M, et al. Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. Radiology. 2020. PMID: 32181728. doi:10.1148/radiol.2020191790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。